Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1345

Sort by

Sort Order Select

Journal Articles

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells

Sofia Mensurado, Carolina Condeço, Diego Sánchez-Martínez, Sara Shirley, Rui M. L. Coelho, Néstor Tirado, Meritxell Vinyoles, Rafael Blanco-Domínguez, Leandro Barros, Beatriz Galvão, Noélia Custódio, Maria Gomes da Silva, Pablo Menéndez, Bruno Silva-Santos

Blood (2024) 143 (15): 1488–1495.

https://doi.org/10.1182/blood.2023022992

Published: 2024

Includes: Supplemental data

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

The bone marrow is the primary site of thrombopoiesis

Nathan L. Asquith, Estelle Carminita, Virginia Camacho, Antonio Rodriguez-Romera, David Stegner, Daniela Freire, Isabelle C. Becker, Kellie R. Machlus, Abdullah O. Khan, Joseph E. Italiano

Blood (2024) 143 (3): 272–278.

https://doi.org/10.1182/blood.2023020895

Published: 2024

Includes: Supplemental data

Journal Articles

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Blood (2024) 143 (2): 118–123.

https://doi.org/10.1182/blood.2023020621

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay

Blood (2024) 143 (1): 57–63.

https://doi.org/10.1182/blood.2023020554

Published: 2024

Includes: Supplemental data

Journal Articles

PF4 activates the c-Mpl–Jak2 pathway in platelets

Richard J. Buka, Samantha J. Montague, Luis A. Moran, Eleyna M. Martin, Alexandre Slater, Steve P. Watson, Phillip L. R. Nicolson

Blood (2024) 143 (1): 64–69.

https://doi.org/10.1182/blood.2023020872

Published: 2024

Includes: Supplemental data

Journal Articles

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A. Saunders, Randall Grose, Chung H. Kok, Jane James, Molly Tolland, Jodi A. Braley, Haley K. Altamura, David T. Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross

Blood (2023) 142 (25): 2192–2197.

https://doi.org/10.1182/blood.2023021119

Published: 2023

Includes: Supplemental data

Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating

Blood (2023) 142 (21): 1784–1788.

https://doi.org/10.1182/blood.2023020158

Published: 2023

Includes: Supplemental data

Journal Articles

Risk of male breast cancer after Hodgkin lymphoma

Simone de Vries, Inge M. Krul, Michael Schaapveld, Cecile P. M. Janus, Saskia E. Rademakers, Judith M. Roesink, Marten R. Nijziel, Yavuz M. Bilgin, Berthe M. P. Aleman, Flora E. van Leeuwen

Blood (2023) 142 (9): 806–811.

https://doi.org/10.1182/blood.2023020940

Published: 2023

Includes: Supplemental data

Journal Articles

Blood group A enhances SARS-CoV-2 infection

Shang-Chuen Wu, Connie M. Arthur, Hau-Ming Jan, Wilfredo F. Garcia-Beltran, Kashyap R. Patel, Matthew F. Rathgeber, Hans P. Verkerke, Narayanaiah Cheedarla, Ryan Philip Jajosky, Anu Paul, Andrew S. Neish, John D. Roback, Cassandra D. Josephson, Duane R. Wesemann, Daniel Kalman, Seth Rakoff-Nahoum, Richard D. Cummings, Sean R. Stowell

Blood (2023) 142 (8): 742–747.

https://doi.org/10.1182/blood.2022018903

Published: 2023

Includes: Supplemental data

Journal Articles

Mutations in atypical hemolytic uremic syndrome provide evidence for the role of calcium in complement factor I

Anuja Java, John Atkinson, Zheng Hu, Nicola Pozzi

Blood (2023) 142 (6): 607–610.

https://doi.org/10.1182/blood.2022019361

Published: 2023

Includes: Supplemental data

Journal Articles

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2023) 142 (2): 141–145.

https://doi.org/10.1182/blood.2022019340

Published: 2023

Journal Articles

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor

Kenneth C. Childers, Nathan G. Avery, Kevin A. Estrada Alamo, Omar Davulcu, Rose Marie Haynes, Pete Lollar, Christopher B. Doering, Carmen H. Coxon, P. Clint Spiegel, Jr.

Blood (2023) 142 (2): 197–201.

https://doi.org/10.1182/blood.2023020181

Published: 2023

Includes: Supplemental data

Journal Articles

Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8–specific signature

Maria Tsagiopoulou, Vicente Chapaprieta, Nuria Russiñol, Beatriz García-Torre, Nikolaos Pechlivanis, Ferran Nadeu, Nikos Papakonstantinou, Niki Stavroyianni, Anastasia Chatzidimitriou, Fotis Psomopoulos, Elías Campo, Kostas Stamatopoulos, José Ignacio Martín-Subero

Blood (2023) 141 (24): 2955–2960.

https://doi.org/10.1182/blood.2022016587

Published: 2023

Includes: Supplemental data

Journal Articles

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge

Tamar Tadmor, Hilel Alapi, Lior Rokach

Blood (2023) 141 (18): 2239–2244.

https://doi.org/10.1182/blood.2022019017

Published: 2023

Includes: Supplemental data

Journal Articles

Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Bruno Fattizzo, Marta Bortolotti, Norma N. Fantini, Andreas Glenthøj, Marc Michel, Mariasanta Napolitano, Simona Raso, Frederick Chen, Vickie McDonald, Irina Murakhovskaya, Josephine Mathilde Iris Vos, Andrea Patriarca, Maria Eva Mingot-Castellano, Giulio Giordano, Margherita Scarrone, Tomás José González-López, Laura Trespidi, Daniele Prati, Wilma Barcellini

Blood (2023) 141 (16): 2016–2021.

https://doi.org/10.1182/blood.2022018890

Published: 2023

Includes: Supplemental data

NARROW

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

The bone marrow is the primary site of thrombopoiesis

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

PF4 activates the c-Mpl–Jak2 pathway in platelets

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Risk of male breast cancer after Hodgkin lymphoma

Blood group A enhances SARS-CoV-2 infection

Mutations in atypical hemolytic uremic syndrome provide evidence for the role of calcium in complement factor I

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor

Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8–specific signature

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge

Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only